Bibliography
- The long view: Pharma R&D productivity – when the cures fail, it makes sense to check the diagnosis. Bernstein Research report; 2010
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(11):711-15
- Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2007;13(1/2):30-7
- Arrowsmith J. Phase III and submission failures: 2007 – 2010. Nat Rev Drug Discov 2011;10(2):1
- Available from: http://www.inpharm.com/news/148299/150211/rd-productivity-worse-previously-reported
- Available from: http://www.inpharm.com/news/101223/2010-pharma-year-review
- Desdouits S, Delaport L, Parnis S. Roadmap for success in oncology. Scrip Exec Brief 2008;1(3):1-11
- From pipeline to market. R&D Dir Exec Brief 2010;16(6):12
- Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6(4):287-93
- Carden CP, Sarker D, Postel-Vinay S, Can molecular biomarker-based patient selection in phase I trials accelerate anti-cancer drug development? Drug Discov Today 2009;15(3/4):88-97
- Druker BJ, Talpaz M, Restra DJ, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7
- Fong PC, Yap TA, Boss DS, Poly(ADP-ribose) polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-19
- Kwak EL, Bang Y-J, Camidge DR, Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. N Engl J Med 2010;363:1693-703
- Chapman PB, Hauschild A, Robert C, Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16